** JonesTrading raises PT on drug developer Monopar Therapeutics MNPR.O to $37 from $9
** Brokerage says MNPR signed agreement with AstraZeneca AZN.L unit Alexion for exclusive worldwide licensing of ALXN-1840 for the treatment of Wilson's disease
** Wilson's disease is a rare genetic condition that causes the buildup of copper to toxic levels
** JonesTrading says ALXN-1840 has the potential to give MNPR a steady cash flow to fund other development efforts
** Brokerage reiterates "buy" rating; PT of $37 is ~94.6% upside on stock's last close
** All of three brokerages rate the stock "buy"; their median PT is $23 - LSEG data
** As of last close, stock up ~1,017.6% YTD
(Reporting by Prakhar Srivastava in Bengaluru)
((Prakhar.srivastava2@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。